Copenhagen Inventor Group

Copenhagen Inventor Group (CIG) is a Danish biotechnology company focused on the development of advanced drug delivery technologies for peptides and proteins. The company's core expertise lies in its proprietary platform designed to enable the oral administration of medications that are typically required to be injected, such as insulin and GLP-1 analogs. CIG's technology utilizes a unique combination of chemical protease inhibitors and absorption enhancers to protect the active ingredients from gastric degradation and facilitate their transport across the intestinal wall. The company operates primarily as an intellectual property holder and licensor, with its most notable partnership being an exclusive global license agreement with Oramed Pharmaceuticals. This collaboration has led to the clinical development of oral insulin (ORMD-0801) and oral GLP-1 (ORMD-0901) candidates for the treatment of diabetes and metabolic disorders.